Related Experiment Video
Updated: Dec 30, 2025

MRI-guided dmPFC-rTMS as a Treatment for Treatment-resistant Major Depressive Disorder
Published on: August 11, 2015
FMF is not always "fever": from clinical presentation to "treat to target"
Maria Cristina Maggio1, Giovanni Corsello2
1Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities "G. D'Alessandro", University of Palermo, Palermo, Italy. mariacristina.maggio@unipa.it.
Abstract:
Familial Mediterranean Fever, a monogenic autoinflammatory disease secondary to MEFV gene mutations in the chromosome 16p13, is characterized by recurrent self-limiting attacks of fever, arthritis, aphthous changes in lips and/or oral mucosa, erythema, serositis. It is caused by dysregulation of the inflammasome, a complex intracellular multiprotein structure, commanding the overproduction of interleukin 1. Familial Mediterranean Fever can be associated with other multifactorial autoinflammatory diseases, as vasculitis and Behçet disease.Symptoms frequently start before 20 years of age and are characterized by a more severe phenotype in patients who begin earlier.Attacks consist of fever, serositis, arthritis and high levels of inflammatory reactants: C-reactive protein, erythrocyte sedimentation rate, serum amyloid A associated with leucocytosis and neutrophilia. The symptom-free intervals are of different length.The attacks of Familial Mediterranean Fever can have a trigger, as infections, stress, menses, exposure to cold, fat-rich food, drugs.The diagnosis needs a clinical definition of the disease and a genetic confirmation. An accurate differential diagnosis is mandatory to exclude infective agents, autoimmune diseases, etc.In many patients there is no genetic confirmation of the disease; furthermore, some subjects with the relieve of MEFV mutations, show a phenotype not in line with the diagnosis of Familial Mediterranean Fever. For these reasons, diagnostic criteria were developed, as Tel Hashomer Hospital criteria, the "Turkish FMF Paediatric criteria", the "clinical classification criteria for autoinflammatory periodic fevers" formulated by PRINTO.The goals of the treatment are: prevention of attacks recurrence, normalization of inflammatory markers, control of subclinical inflammation in attacks-free intervals and prevention of medium and long-term complications, as amyloidosis. Colchicine is the first step in the treatment; biological drugs are effective in non-responder patients.The goal of this paper is to give a wide and broad review to general paediatricians on Familial Mediterranean Fever, with the relative diagnostic, clinical and therapeutic aspects.
Insights
Familial Mediterranean Fever (FMF) is an autoinflammatory disease caused by MEFV gene mutations, leading to recurrent fever and inflammation. Early diagnosis and treatment with colchicine or biologics are crucial for managing FMF and preventing complications.
Area of Science:
- Genetics and Immunology
- Pediatric Rheumatology
- Autoinflammatory Diseases
Background:
- Familial Mediterranean Fever (FMF) is a monogenic autoinflammatory disorder stemming from MEFV gene mutations.
- It involves inflammasome dysregulation, leading to interleukin-1 overproduction and recurrent inflammatory attacks.
- Symptoms often manifest before age 20, with earlier onset correlating to a more severe phenotype.
Purpose of the Study:
- To provide pediatricians with a comprehensive review of Familial Mediterranean Fever.
- To cover diagnostic, clinical, and therapeutic aspects of FMF.
- To emphasize the importance of accurate diagnosis and management strategies.
Main Methods:
- Review of clinical manifestations, including fever, serositis, and arthritis.
- Discussion of diagnostic approaches, encompassing clinical criteria and genetic confirmation.
- Analysis of treatment strategies, focusing on colchicine and biological agents.
Main Results:
- FMF attacks are characterized by fever, serositis, arthritis, and elevated inflammatory markers.
- Diagnosis requires clinical definition and genetic confirmation, with established criteria like Tel Hashomer and PRINTO.
- Treatment aims to prevent attacks, normalize inflammation, and avert long-term complications such as amyloidosis.
Conclusions:
- Accurate differential diagnosis is essential to distinguish FMF from other inflammatory conditions.
- Colchicine is the primary treatment, with biological drugs available for non-responders.
- Effective management of FMF is vital for preventing disease progression and improving patient outcomes.
Related Concept Videos
Therapeutic Drug Monitoring: Overview and Classification
Therapeutic Drug Monitoring: Affecting Factors
Clinical Trials: Overview
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Treatment Resistant Cancers
Preclinical Development: Overview

